【レポートの概要（一部）】
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 11
2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q3 2013 15
2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q3 2013 15
2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q3 2013 17
2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q3 2013 18
2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q3 2013 19
2.4.1 Shoppers Drug Mart Receives Ontario Court Approval for Its Acquisition by Loblaw for US$11.93 Billion 19
2.4.2 Amgen Completes Tender Offer to Acquire Onyx Pharma for up To US$10.4 Billion 21
2.4.3 Community Health Systems to Acquire Health Management Associates for up to US$7.6 Billion 22
2.4.4 Fresenius to Acquire 43 Hospitals from Rhon-Klinikum for US$4.1 Billion 23
2.4.5 Tenet Healthcare Prices Private Placement of Notes Due 2022 for US$2.8 Billion 24
3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 25
3.1 Pharmaceuticals & Healthcare, Global, M&A, Q3 2013 25
3.1.1 Top M&A Deals in Q3 2013 26
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q3 2012 – Q3 2013 27
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q3 2013 29
3.2.1 Top Initial Public Offerings in Q3 2013 31
3.2.2 Top Secondary Offerings in Q3 2013 31
3.2.3 Top PIPE Deals in Q3 2013 31
3.2.4 Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q3 2012-Q3 2013 32
3.2.5 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q3 2012 – Q3 2013 33
3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q3 2013 35
3.3.1 Top Venture Financing Deals in Q3 2013 36
3.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2013 37
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2013 38
3.3.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q3 2012 – Q3 2013 39
3.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Last Four Quarters 41
3.3.6 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q3 2012 – Q3 2013 43
3.4 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q3 2013 44
3.4.1 Top Private Equity Deals in Q3 2013 45
3.4.2 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q3 2012 – Q3 2013 46
4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2013 48
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2013 48
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q3 2012 – Q3 2013 50
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2013 52
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q3 2013 54
4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2013 54
4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q3 2013 55
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2012 – Q3 2013 56
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q3 2012 – Q3 2013 58
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q3 2012 – Q3 2013 59
4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2012 – Q3 2013 61
5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q3 2013 63
5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q3 2013 63
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2012 – Q3 2013 65
5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q3 2013 67
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q3 2013 67
5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q3 2013 68
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q3 2012 – Q3 2013 69
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q3 2012 – Q3 2013 71
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2012 – Q3 2013 73
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2012 – Q3 2013 74
5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q3 2012 – Q3 2013 76
6 Pharmaceuticals & Healthcare, Global, M&A Financial Analysis 78
6.1 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value versus Median Deal Value, Q3 2012 – Q3 2013 78
6.2 Pharmaceuticals& Healthcare, Global Acquisitions, Average Price Earnings of Acquired Companies, Q3 2012 – Q3 2013 80
6.3 Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q3 2012 – Q3 2013 82
6.4 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q3 2012 – Q3 2013 84
6.5 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Market Price Per Share, Q3 2012 – Q3 2013 86
6.6 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Book Value Per Share, Q3 2012 – Q3 2013 88
6.7 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q3 2012 – Q3 2013 90
7 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 92
7.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q3 2013 92
7.1.1 Oncology – Deals of the Quarter 94
7.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q3 2013 96
7.2.1 Central Nervous System – Deals of the Quarter 98
7.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q3 2013 101
7.3.1 Infectious Disease – Deals of the Quarter 103
7.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q3 2013 105
7.4.1 Immunology – Deals of the Quarter 107
7.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q3 2013 108
7.5.1 Metabolic Disorders – Deals of the Quarter 110
7.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q3 2013 112
7.6.1 Cardiovascular – Deals of the Quarter 114
7.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q3 2013 116
7.7.1 Gastrointestinal – Deals of the Quarter 118
7.8 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q3 2013 119
7.8.1 Dermatology – Deals of the Quarter 121
7.9 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q3 2013 122
7.9.1 Respiratory – Deals of the Quarter 124
7.10 Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q3 2013 126
7.10.1 Ophthalmology – Deals of the Quarter 128
8 Deal Summary by Geography 130
8.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q3 2013 130
8.1.1 North America – Deals of the Quarter 132
8.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q3 2013 135
8.2.1 Europe – Deals of the Quarter 137
8.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q3 2013 139
8.3.1 Asia-Pacific – Deals of the Quarter 141
8.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q3 2013 144
8.4.1 Rest of the World – Deals of the Quarter 146
9 Pharmaceuticals & Healthcare, Global, Top Advisors 148
9.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Last One Year 148
9.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Last One Year 150
10 Appendix 152
11 Further Information 156
11.1 Methodology 156
11.2 About GlobalData 157
11.3 Disclosure information 158
11.4 Disclaimer 158
【レポート販売概要】
■ タイトル：事業提携・ライセンシング・投資・M&A動向（四半期別）：Q3 2013■ 英文：Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2013
■ 発行日：2013年11月30日
■ 調査会社：GlobalData
■ 商品コード：GDATA403162973
■ 調査対象地域：グローバル
- 建築用レンダーソフトの世界市場2016-2020About Architectural Rendering Software Rendering is the graphical process of creating a visual scene through computer-generated light waves. It creates the visualization of 3D objects based on the strength of light waves or particles that are created by the rendering software itself. Virtualization software is used to develop a real animation world around 3D objects that are created by the renderi …
- 二輪車用スターターモーターの世界市場2019-2023About this market Improvement in performance of low-displacement two-wheelers to drive growth in the market. Two-wheeler manufacturers are developing and launching new and powerful models of scooters and motorcycles to penetrate and utilize the higher purchasing power of the population in the emerging markets in APAC. They will be performing certain changes in the internal components like starter …
- アプリケーションセキュリティの世界市場予測（～2022年）：ソリューション、サービス“Increased sophistication of cyber-attack techniques is driving the growth of the application security market.”MarketsandMarkets expects the global application security market to grow from USD 2.79 billion in 2017 to USD 9.0 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 26.4%. As attackers have shifted their focus from traditional network layer attacks to application layer attacks, t …
- ビデオストリーミング及び放送機器の世界市場：ビデオABRインフラ、ビデオトランスコーダ、ビデオエンコーダ、ビデオIRDAbout Video Streaming and Broadcasting Equipment Video streaming and broadcasting equipment consists of devices and software programs such as encoders, transcoders, and IRDs. These devices use ABR technology to stream and broadcast videos to various devices such as TVs, computers, and phones. This technology streams content based on the bandwidth of the receiving device. Technavio's analysts forec …
- 世界の軍用固定翼航空機の市場動向2013-2023Why was the report written? “The Global Military Aircraft Market 2013-2023” offers the reader detailed analysis of the global military aircraft market over the next ten years, alongside potential market opportunities to enter the industry, using detailed market size forecasts. What are the key drivers behind recent market changes? Many countries are expected to replace their ageing military aircra …
- Black Ridge Oil & Gas Inc.：石油・ガスの開発・生産動向及びコスト分析- Q3, 2013Black Ridge Oil & Gas Inc. Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2013 Summary Black Ridge Oil & Gas Inc. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essent …
- 個別指導の世界市場2016-2020About Private Tutoring Private tutoring is a part of the shadow education system as it is offered outside the mainstream education system. The private tutoring industry has emerged following the extensive standardization of the education sector. This standardization essentially refers to the provision of examination preparation services to students to help them score well in entrance tests. Techna …
- ポリフッ化ビニリデン(PVDF)のグローバル市場動向（～2019）The report covers the global PVDF market. It further divides the market on the basis of end user industry, applications, geography. The market data for these types is given with respect to volume (metric tons) and value ($thousand). The global market value of PVDF was estimated to be $596,009.6 thousand in 2012 and is projected to grow with a CAGR of about 7.4% from 2014 to 2019. The data mentione …
- 世界の非破壊試験設備市場動向（2014-2018）About NDT Equipment NDT equipment is used to examine or evaluate the properties of an object, material or system without damaging it. This equipment is used in various applications, including weld verification and structural mechanics, across industries such as Automotive, Aerospace, Oil and Gas, and Power Generation. TechNavio's analysts forecast the Global NDT Equipment market will grow at a CAG …
- 世界の軍事シミュレーション及び仮想訓練市場：市場規模及びドライバーSummary This report provides readers with a comprehensive analysis of the Military Simulation and Virtual Training market through 2015-2025, including highlights of the demand drivers and growth stimulators for Military Simulation and Virtual Training. It also provides an insight on the spending pattern and modernization pattern in different regions around the world. Key Findings The global milita …
- WiFi対応のLTEスモールセルゲートウェイ予測2013-2020（WiFi Enabled LTE Small Cell Gateway Forecasts: 2013 ～2020）Driven by large scale LTE investments and the high penetration of embedded WiFi capability in consumer electronic devices, both fixed and mobile, a number of wireless carriers are taking a keen interest in WiFi enabled LTE gateways. A WiFi enabled LTE small cell gateway (or base station) is an emerging network element, which has an LTE interface towards the carrier network and a WiFi interface tow …
- 生コンクリートの世界市場2017-2021ABSTRACTAbout Readymix Concrete Ready-mix concrete is manufactured in a factory or a plant, within certain specific guidelines, and then delivered to the construction site through a truck equipped with transit mixers. Ready-mix concrete is manufactured in a factory or a plant, within certain specific guidelines, such as in the ratio of 3:2:1, i.e., 3 parts aggregates, 2 parts water, and 1 part cem …
- 不安障害とうつ病治療の世界市場分析：製品別（抗うつ薬、SSRI、SNRI、ベンゾジアゼピン、装置と治療、TNS、DBS、VBS）、症状別（MDD、OCD、恐怖症）、セグメント予測、2014-2025The global anxiety disorders and depression treatment market is expected to reach a value of USD 18.3 billion by 2025. The rising incidence of depression worldwide is anticipated to drive the market growth in the coming years. Increasing adoption of devices and psychotherapies has resulted in the declining demand for antidepressants in the recent years. The rising geriatric population prone to dep …
- 世界の自動車ナイトビジョンシステム(NVS)市場2015The Global Automotive Night Vision Systems (NVS) Industry Report 2015 is a professional and in-depth study on the current state of the Automotive Night Vision Systems (NVS) industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Automotive Night Vision Systems (NVS) market analysis is provided for the inte …
- 狂犬病ワクチンのグローバル市場機会分析（MarketVIEW: Rabies vaccines）Rabies is a viral zoonosis caused by all members of the Lyssavirus genus and mostly spread by canine vectors. The disease, if untreated is 100% fatal, although almost 100% preventable through timely postexposure prophylaxis (PEP). Rabies causes tens of thousands of deaths each year, mainly in rural areas of Africa and Asia. Novartis Vaccines and Sanofi are the only Western producers vaccines for r …
